News | Radiation Therapy | August 27, 2019

PTW to Feature New Dosimetry Technology at ASTRO 2019

Offerings will include QA equipment for MR-guided and stereotactic therapy

Beamscan MR 3D water phantom – the first 3-D water phantom for magnetic resonance (MR)-guided radiotherapy

August 27, 2019 — Radiation dosimetry company PTW announced plans to exhibit its full range of radiation therapy dosimetry solutions for acceptance, commissioning, beam data acquisition and patient-specific quality assurance (QA) at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-19 in Chicago.

In its booth, PTW will exhibit and demonstrate its latest solutions and most recent product developments including:

  • Beamscan MR 3D water phantom – the first 3-D water phantom for magnetic resonance (MR)-guided radiotherapy, available in two ready-to-use models for Elekta Unity and ViewRay MRIdian;
  • Beamscan 3D water phantom – fast to set up and easy to use for all acceptance testing and commissioning needs, now also available for the Halcyon system;
  • Starcheck maxi MR array – a comprehensive solution for machine QA, from high-resolution measurements up to 40 cm x 40 cm in magnetic fields to legally required documentation;
  • MR-conditional detectors – a wide range of PTW's detector brands that are now available for MR dosimetry;
  • Octavius 4-D modular patient and machine QA systems – for the latest radiotherapy techniques, including Halcyon, stereotactic radiosurgery (SRS) and MRgRT. Also introducing the Octavius Detector 1600 SRS for 3-D dose verification of complex SRS/SBRT (stereotactic body radiation therapy) treatment plans;
  • Ruby phantom – a new modular QA phantom with multiple inserts for comprehensive system QA, linear accelerator (linac) QA and patient QA;
  • microSilicon diode detector – the new silicon diode detector for small photon and all electron fields; and
  • Track-it 2.0 QA data management software – a versatile, web-based QA data management software that integrates QA data from different sources, devices and sites into a single platform.

For more information: www.ptwdosimetry.com

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...